Jeric Hernandez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeric Hernandez has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Mark Yarchoan
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
24 shared publications - Waqar Arif
Johns Hopkins University 4
24 shared publications - Won Jin Ho
Johns Hopkins University 4 Department of Oncology, School of Medicine Baltimore, Maryland
24 shared publications - Aditi Guha
Genentech 11 San Francisco, CA
23 shared publications - Carlotta Pazzi
Sidney Kimmel Comprehensive Cancer Center 3
23 shared publications - Caroline Ellis
Sidney Kimmel Comprehensive Cancer Center 3
23 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 11 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
ROC curve for baseline plasma IL-17F as a predictor of excellent response compared to non-excellent response.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 11 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
ROC curve for baseline plasma IL-17F as a predictor of excellent response compared to non-excellent response.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
Cytokine fold-change from baseline to early-on-treatment.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
Cytokine fold-change from baseline to early-on-treatment.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 10 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
Kaplan–Meier curves comparing on-treatment IL-8 less than or equal to median to Il-8 greater than median for both (A) PFS and (B) OS.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 10 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
Kaplan–Meier curves comparing on-treatment IL-8 less than or equal to median to Il-8 greater than median for both (A) PFS and (B) OS.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
IL-17F above lower limit of detection associates with excellent response compared to non-excellent response.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
IL-17F above lower limit of detection associates with excellent response compared to non-excellent response.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 12 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
Change from baseline to early-on treatment timepoint in Th17 proportions in Excellent Responders is shown
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 12 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
Change from baseline to early-on treatment timepoint in Th17 proportions in Excellent Responders is shown
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
Grade 2+ irAE Development is significantly associated with Excellent Response status.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
Grade 2+ irAE Development is significantly associated with Excellent Response status.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 15 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
ROC curves comparing discriminative ability of (A) baseline IL-21 and baseline NLR, (B) baseline IL-23 and baseline NLR, and (C) baseline IL-23 and on-treatment NLR for predicting excellent response.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 15 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
ROC curves comparing discriminative ability of (A) baseline IL-21 and baseline NLR, (B) baseline IL-23 and baseline NLR, and (C) baseline IL-23 and on-treatment NLR for predicting excellent response.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 13 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
Heatmap of log2 fold-change from baseline to early-on treatment for activation, memory, effector/proliferation, and exhaustion markers across CyTOF-derived immune cell subsets, shown separately for excellent and non-excellent responders.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 13 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
Heatmap of log2 fold-change from baseline to early-on treatment for activation, memory, effector/proliferation, and exhaustion markers across CyTOF-derived immune cell subsets, shown separately for excellent and non-excellent responders.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 14 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
(A)On-treatment NLR in Excellent vs Non-Excellent Responders (Wilcoxon Rank-Sum Test).
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 14 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
(A)On-treatment NLR in Excellent vs Non-Excellent Responders (Wilcoxon Rank-Sum Test).
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
(A) PFS and (B) OS Curves for the total cohort stratified by excellent response status
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors
(A) PFS and (B) OS Curves for the total cohort stratified by excellent response status